Search

Displaying results 1241 - 1250 of 5384 in total
  1. Drug

    Dimercaprol

    go.drugbank.com/drugs/DB06782
    Approved

    Dimercaprol has toxic potential, and its use may be followed by a variety of adverse effects. … Dimercaprol is a traditional chelating agent developed by British biochemists at Oxford University during World War II.

  2. Drug

    Motexafin gadolinium

    go.drugbank.com/drugs/DB05428
    Investigational

    Motexafin gadolinium is studied in the treatment of cancer by Pharmacyclics.

  3. Drug

    Bufexamac

    go.drugbank.com/drugs/DB13346
    ApprovedWithdrawn

    Bufexamac was also withdrawn by the EMA in April 2010. … The use of bufexamac has been discontinued in Canada and the United States, which may be due to undetermined clinical efficacy and a high prevalence of contact sensitization [A32822].

    Categories: Antiinflammatory Preparations, Non-Steroids for Topical Use
  4. Drug

    Iron Dextran

    go.drugbank.com/drugs/DB00893
    ApprovedInvestigationalVet approved

    Iron dextran is a dark brown, slightly viscous liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use.

  5. Drug

    Carfentanil

    go.drugbank.com/drugs/DB01535
    IllicitInvestigationalVet approved

    Carfentanil is intended for large-animal use only as its extreme potency makes it inappropriate for use in humans. … Carfentanil was first synthesized in 1974 by a team of chemists at Janssen Pharmaceutica which included Paul Janssen.

  6. Drug

    Tecovirimat

    go.drugbank.com/drugs/DB12020
    ApprovedInvestigational

    [L3626, L3614] Tecovirimat was later approved by Health Canada in December 2021,[L39397] followed by the approval from the European Commission in January 2022. … [A35131,A35143] Tecovirimat was approved by the FDA in July 2018 as the first drug ever approved to treat smallpox.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  7. Drug

    Rituximab

    go.drugbank.com/drugs/DB00073
    ApprovedInvestigational

    On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808]. … It was originally approved by the U.S.

  8. Drug

    Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB14459
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

    Mixtures: Medical Provider Single Use EZ Flu Shot Afluria 2016-2017, Medical Provider Single Use EZ Flu Shot Fluvirin 2016-2017
  9. Drug

    Lapatinib

    go.drugbank.com/drugs/DB01259
    ApprovedInvestigational

    It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. … Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer.

  10. Drug

    Chlormezanone

    go.drugbank.com/drugs/DB01178
    ApprovedWithdrawn

    It has been suggested for use in the treatment of muscle spasm.